Tenofovir/emtricitabine

CDC Issues Guidance on Pre-Exposure Prophylaxis for HIV in Heterosexual Adults.

Posted by

1


The CDC has released interim recommendations on providing pre-exposure prophylaxis (PrEP) to prevent HIV in very-high-risk heterosexual adults — for example, those whose partners are infected.

Among the recommendations, published in MMWR:

  • Before prescribing PrEP, clinicians should screen patients for sexually transmitted infections and hepatitis B.
  • Clinicians should explain to women that the effect of the drugs on the developing fetus is not fully known, but no harms have been reported so far. Breast-feeding mothers should not receive PrEP.
  • When pregnant women take PrEP, clinicians can anonymously submit data on the pregnancy to the Antiretroviral Pregnancy Registry.
  • Tenofovir disoproxil fumarate (TDF) 300 mg plus emtricitabine (FTC) 200 mg (i.e., one Truvada tablet) should be taken daily, and patients should be given no more than a 90-day supply.
  • HIV tests should be administered every 2 to 3 months.
  • Women should take a pregnancy test at each follow-up visit.

Source: MMWR

 

HIV Treatment as Prevention: Optimising the Impact of Expanded HIV Treatment Programmes.

Posted by

0


Resources for expanding ART in the short term may be limited, so the question is how to generate the most prevention benefit from realistic potential increases in the availability of ART. Although not a formal systematic review, here we review different ways in which access to ART could be expanded by prioritising access to particular groups based on clinical or behavioural factors. For each group we consider (i) the clinical and epidemiological benefits, (ii) the potential feasibility, acceptability, and equity, and (iii) the affordability and cost-effectiveness of prioritising ART access for that group. In re-evaluating the allocation of ART in light of the new data about ART preventing transmission, the goal should be to create policies that maximise epidemiological and clinical benefit while still being feasible, affordable, acceptable, and equitable.

 

Source: PLOS